Omega-3 fatty acid supplementation and cardiovascular disease events [4]

JAMA

Volumn 309, Issue 1, 2013, Pages 28-29

  Galli, Claudio ^a   Brenna, J Thomas ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIET SUPPLEMENTATION; DRUG USE; ERYTHROCYTE; FAT INTAKE; HEART MUSCLE CELL; HIGH RISK PATIENT; HUMAN; LETTER; META ANALYSIS (TOPIC); NERVE CELL; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SECONDARY PREVENTION; MORTALITY; NOTE;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS;

EID: 84871733234     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.116648     Document Type: Letter

References (3)

1. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024-1033.
2. Hibbeln JR, Nieminen LRG, Blasbalg TL, Riggs JA, Lands WEM. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr. 2006;83(6)(suppl):1483S-1493S.
3. Harris WS. International recommendations for consumption of long-chain omega-3 fatty acids. J Cardiovasc Med (Hagerstown). 2007;8(suppl 1):S50-S52.